Bazemore Robert B 4

What Happened
Robert B. Bazemore, a director of Nuvation Bio Inc. (NUVB), was granted a derivative award covering 123,397 shares on May 21, 2026. The transaction is reported as an award/grant (code A) with a reported transaction price of $0.00 (the filing shows a derivative security — an option — rather than a market purchase). The Form 4 reports the grant amount (123,397) but does not assign a market value as a purchase or sale.

Key Details

• Transaction date: May 21, 2026; Form 4 filed May 26, 2026 (5 days after the transaction).
• Reported transaction type/price: Grant/Award of derivative shares at $0.00 (code A).
• Shares affected: 123,397 derivative shares (option award).
• Shares owned after transaction: Not disclosed in the filing.
• Vesting: Footnote states 100% of the shares subject to the option vest on the earlier of (i) the one‑year anniversary of the grant date (May 21, 2027) or (ii) the next shareholder annual meeting, subject to continuous service.
• Timeliness: Filed May 26 for a May 21 transaction — outside the typical two‑business‑day Form 4 window, which may indicate a late filing.

Context
This was a compensation grant (an option-style award) to a director, not an open‑market purchase or sale. The award vests based on continued service and timing of the next shareholder meeting, and it was not exercised or sold at the time of filing. Such grants are commonly used for director compensation and do not, by themselves, indicate buying or selling sentiment.